Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Q2 2025 Earnings Presentation
28 slides from Cytosorbents's earnings presentation, Aug 7, 2025
Slide 1: Q2 2025 Financial Results and Recent Business Highlights Conference Call
CytoSorbents Corporation Nasdaq: CTSO Q2 2025 Financial Results and Recent Business Highlights Conference Call August 1 | 7, 2025
Slide 2: Conference Call Participants
Conference Call Participants Phillip Chan, MD, PhD Peter J. Mariani, CPA Chief Executive Officer Chief Financial Officer Moderator: Adanna Alexander, PhD 2 | VP Investor Relations, ICR Healthcare
Slide 3: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 4: Operational Update
Operational Update Phillip Chan, MD, PhD Chief Executive Officer 4 |
Slide 5: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology for removing toxins and harmful substances from the blood • High margin “razorblade” that is “plug and play” into existing hospital blood pumps • Two main products leveraging the underlying polymer technology CytoSorb • Treatment of l
Slide 6: Agenda
Agenda • Q2 2025 Performance Summary • Regulatory/Clinical Update on DrugSorb-ATR • Turning the Tide in Sepsis and Septic Shock with CytoSorb • Financial Results and Cash 6 |
Slide 7: Q2 2025 Performance Summary
Q2 2025 Performance Summary • Q2 2025 Revenue was $9.6M, a 9% increase vs $8.8M a year ago, or 4% on a constant currency basis • Performance led by Germany growth of 22% year-over-year and sequentially following pro-active reorganization initiated in Q1, and continued strength in our other direct EU
Slide 8: DrugSorb-ATR Update
§ DrugSorb Update ATR CytoSorbents.
Slide 9: Blood Thinners Can Cause Serious Perioperative Bleeding
Blood Thinners Can Cause Serious Perioperative Bleeding DrugSorb-ATR can help • Acute heart attack patients commonly receive blood thinners like Brilinta® to improve clinical outcomes • But Brilinta® (ticagrelor) can cause serious and potentially life-threatening bleeding in patients that need to un
Slide 10: Continued Real World Validation
Continued Real World Validation Continue to demonstrate and be recognized for the ability to address the critical global unmet need of reducing serious bleeding in CABG patients on Brilinta® • At EuroPCR (May 2025), Prof. Robert Storey presented a new comparative analysis of bleeding risk in 150 CAB
Slide 11: FDA and Health Canada Regulatory Update
FDA and Health Canada Regulatory Update • U.S. FDA De Novo submission and Medical Device License application to Health Canada included STAR-T RCT data and STAR registry real world evidence (RWE) • Interactive review with FDA resolved many issues, however, a denial letter was issued April 25, 2025 •
Slide 12: CytoSorb Update
12 CytoSorl) Update CytoSorbents
Slide 13: Turning the Tide of Sepsis and Septic Shock
Turning the Tide of Sepsis and Septic Shock 13 13 |
Slide 14: Sepsis and Septic Shock are Deadly
Sepsis and Septic Shock are Deadly • Sepsis is a complex life-threatening condition where the inflammatory response to a serious infection can spiral out of control, fueled by the excessive production of cytokines (cytokine storm), bacterial toxins, and other inflammatory agents • Unchecked, massive
Slide 15: CytoSorbents is Leading a New Era in Sepsis Treatment
CytoSorbents is Leading a New Era in Sepsis Treatment For more than a decade, CytoSorbents has collaborated with clinicians and scientists around the world to advance the treatment of sepsis and septic shock by complementing traditional antibiotics with the broad-spectrum capability of CytoSorb Cyto
Slide 16: CytoSorb Enables Multi-Faceted Attack on Septic Shock
CytoSorb Enables Multi-Faceted Attack on Septic Shock A wealth of published, peer-reviewed studies support the broad mechanisms of action of CytoSorb that enable a comprehensive and multi-faceted attack on septic shock – from beginning to end CytoSorb enables the Core Treatment Goals in Septic Shock
Slide 17: The Key to Success: Right Patient, Right Timing, Right Dosing
The Key to Success: Right Patient, Right Timing, Right Dosing Right Patient Just like antibiotics, CytoSorb works most effectively when: Highest • Treat Early Chance for • Treat Intensively Good Cinical • Compete the Full Course of Treatment Outcome Right Right Timing Dose 17 |
Slide 18: 2025: COSMOS Registry Highlights Treatment Strategy Success
2025: COSMOS Registry Highlights Treatment Strategy Success COSMOS registry, patient characteristics CAPILLARY LUNG • Data from 150 patients analyzed SHOCK LEAK FUNCTION • Critical care indications: Septic shock (57.6%) Cardiogenic shock (12.9%) Rhabdomyolysis (10.6%) Acute/acute-on-chronic liver fa
Slide 19: 2025: Early & Intensive Treatment with More Blood Treated Works Best
2025: Early & Intensive Treatment with More Blood Treated Works Best • Large, retrospective single center study • 175 patients with septic shock treated with CytoSorb • Evaluated the impact of early versus late, and low versus high intensity treatment with CytoSorb on mortality compared to predicted
Slide 20: CytoSorb Septic Shock Meta-Analysis
CytoSorb Septic Shock Meta-Anaysis • Meta-analysis of 744 septic shock patients from 1 RCT and 8 observational studies from 2019-2024, of which 449 patients were treated with CytoSorb • CytoSorb reduced in-hospital mortality (OR 0.64, p=0.04) • 28-30-day mortality was also halved with CytoSorb (OR 0
Slide 21: World Sepsis Day Global Webinar – September 10, 2025
World Sepsis Day Global Webinar – September 10, 2025 Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb Date: Wednesday, September 10, 2025 Time: 11:00 AM EDT Hosted by: Dr. Phillip Chan, MD, PhD Webinar registration required: https://cyto.news/webinar-sepsis/sep10 21 21
Slide 22: Financial Highlights
Financial Highlights Peter J. Mariani Chief Financial Officer 22 |
Slide 23: Revenue and Gross Margin
Revenue and Gross Margin • Revenue led by 22% growth year-over-year 2Q25 2Q24 YoY Change and sequentially in Germany with continued strength in our other direct territories • Distributor sales were among our best ever, Revenue $9.6m $8.8m +9% second only to a record Q2 2024 Constant currency growth
Slide 24: Operating Results
Operating Results 2Q25 2Q24 YoY Change Total operating $10.4m $10.1m 3% increase expenses Operating loss $3.6m $3.6m flat $1.9m ($4.3m) Net income / (loss) ($0.03 / basic and diluted sh) ($0.08 / basic and diluted sh) Adjusted net income / ($3.7m) ($2.8m) (loss) ($0.06 / basic sh; $0.05 / diluted sh
Slide 25: Strong Balance Sheet Driving Core Business toward Cash Flow Breakeven
Strong Balance Sheet Driving Core Business toward Cash Flow Breakeven as we exit 2025 • $11.7 million in cash, cash equivalents and restricted cash at June 30, 2025 • Includes $1.7 million received in April from Sale of NOL and R&D credits • $5.0 million second tranche available at our option on our
Slide 26: Closing Remarks
Closing Remarks Phillip Chan, MD, PhD Chief Executive Officer 26 |
Slide 27: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition CytoSorb is an established, international core business in critical care and cardiac surgery with $35M+ in high margin product sales with expectations for growth due to: • Significant market opportunity, targeting major unmet medical needs • “Right patient at
Slide 28: Q&A Session
Q&A Session NASDAQ: CTSO Company Contact: Peter J. Mariani pmariani@cytosorbents.com Investor Relations Contact: Aman Patel, CFA & Adanna Alexander, PhD ICR Healthcare ir@cytosorbents.com 28